Robert B. Geller - 01 Feb 2023 Form 4 Insider Report for Aravive, Inc.

Reporting relationship: Chief Medical Officer
Issuer ticker: N/A
Reported as of: 01 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Feb 2023, 15:24:35 UTC
Prior SEC filing: 05 Jul 2022
Source filing: View source filing
Reporting owner signature: /s/ Abel Svitavsky, Attorney-in-fact

Key filing fact

Robert B. Geller filed Form 4 for Aravive, Inc. on 02 Feb 2023.

Key facts

This page summarizes Robert B. Geller's Form 4 filing for Aravive, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Feb 2023, 15:24.

Change

Previous filing in this sequence was filed on 05 Jul 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARAV transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +400,000
Change %
Price: $0.000000
Shares after: 400,000
Date: 01 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 400,000
Exercise price: $1.67
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These options vest over three years with 50% vesting on the one-year anniversary of the date of grant and the remaining 50% vesting on a pro rata basis on a monthly basis over a two-year period commencing on the month following the one-year anniversary of the grant date.